Mikami, Yohei

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Gastroenterology and Hepatology) ( Shinanomachi )

Position

Associate Professor

External Links
Scopus Paper Info  
Paper Count: 127 Citation Count: 5761 h-index: 39

Click to view the Scopus page. The data was downloaded from Scopus API in May 31, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲

Career 【 Display / hide 】

  • 2008.04
    -
    2018.03

    Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine,, Assistant Professor

  • 2013.09
    -
    2018.03

    National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Postdoctoral Fellow/Supplemental Visiting Fellow

  • 2018.04
    -
    2020.03

    Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine,, Project Assistant Professor

  • 2020.04
    -
    2020.09

    Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine,, Assistant Professor

  • 2020.10
    -
    2021.03

    Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine,, Assistant Professor

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2008.04
    -
    2012.03

    Keio University, Graduate School of Medicine

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • PhD (Medicine), Keio University, Coursework, 2012

Page Top ▲
 

Research Keywords 【 Display / hide 】

  • Inflammatory bowel disease

  • Mucosal immunology

  • Tissue regeneration and fibrosis

  • Neuroimmunology

Page Top ▲
 

Papers 【 Display / hide 】

  • STAT4 drives optimal expansion and transcriptional repression of type I interferon pathway in inflammatory ILC2

    Pietropaolo G., Scarno G., Candelotti A.M., Garzillo G., Di Censo C., Peruzzi G., Fionda C., Stabile H., Sozio F., D’Aquino C., Molfetta R., Leone F., Cinicola B.L., Gori A., Ciancaglini C., Santopolo S., Quatrini L., Zicari A.M., Shih H.Y., Mikami Y., Gismondi A., Bernardini G., Hsu K.C., Santoni A., Sozzani S., Laffranchi M., Sciumè G.

    Cellular and Molecular Life Sciences 83 ( 1 )  2026.12

    ISSN  1420682X

    　View Summary

    Innate immune cells respond rapidly to environmental cues through signal-regulated transcription factors (SRTFs) that sense changes in the tissue microenvironment. Signal transducer and activator of transcription (STAT) proteins are critical regulators of cytokine signaling and determine polarized immune responses. Herein, we reveal that activated type 2 innate lymphocytes (ILC2s) express STAT4, a SRTF canonically linked to type 1 immunity. STAT4 expression is induced in ILC2s upon activation by the alarmin IL-25 and linked with accumulation of lung inflammatory ILC2s (iILC2s). Despite elevated STAT4 expression, iILC2s do not acquire type 1 features, such as interferon (IFN)-γ production or T-bet expression and do not respond to IL-12 stimulation. Instead, STAT4 is activated by type I IFNs and supports the maintenance of the iILC2 pool. Transcriptomic analysis of Stat4-deficient ILC2s reveals enhanced type I IFN signaling and impaired proliferation, suggesting that STAT4 functions to antagonize IFN-driven suppression. Our data uncover a novel regulatory axis in which IL-25-induced STAT4 expression equips ILC2s to modulate interferon responses and to prevent aberrant autocrine function of type I IFNs, thus sustaining inflammatory effector populations during immune activation. These findings broaden the understanding of ILC2 activation and suggest new avenues for modulating innate lymphocytes in inflammatory diseases.

  • Characterization of Computed Tomography Colonography Findings of Ulcerative Colitis-Associated Neoplasia

    Kaieda Y., Sugimoto S., Suzuki T., Matsumoto S., Kiyohara H., Takabayashi K., Yoshimatsu Y., Okabayashi K., Shigeta K., Sakakibara R., Wakisaka Y., Murakami S., Jinzaki M., Iwao Y., Mikami Y., Kanai T.

    Inflammatory Bowel Diseases 32 ( 5 ) 875 - 883 2026.05

    ISSN  10780998

    　View Summary

    Background: Computed tomography colonography (CTC) is increasingly utilized for the evaluation of colorectal neoplasms. However, in patients with ulcerative colitis (UC), current European Crohn’s and Colitis Organisation guidelines recommend CTC only for limited indications, such as the presence of strictures. This study aimed to assess the potential clinical utility of CTC by examining its detectability of UC-associated neoplasia (UCAN) lesions. Methods: This single-center, retrospective observational study included consecutive patients with UC who underwent preoperative CTC and were scheduled for pancolectomy for UCAN between January 2014 and June 2024. Lesion detectability on CTC was assessed in comparison with endoscopic findings, histopathological tumor depth, and morphological characteristics. Multivariable logistic regression was performed to identify factors associated with detectability on CTC. Results: Among 50 patients with 71 histologically confirmed lesions, 49% (35/71) were detectable by CTC. Detection was highest in advanced cancer (100%, 7/7), sessile (80%, 4/5) and depressed (80%, 8/10) morphologies, and lower in non-polypoid types such as superficial elevated (58%, 14/24) and flat (8%, 2/25) lesions. Detection by depth was 29% (12/42) for intramucosal, 75% (9/12) for submucosal, 100% (5/5) for muscularis propria, 73% (8/11) for subserosa/adventitia, and 100% (1/1) for serosal lesions. Flat morphology (adjusted odds ratio [aOR], 0.06; 95% confidence interval [CI], 0.01-0.27) and intramucosal invasion (aOR, 0.10; 95% CI, 0.02-0.46) were independently associated with non-detection. Conclusions and Relevance: Despite preoperative awareness of UCAN, CTC demonstrated limited sensitivity. While CTC may serve a complementary role in selected cases, endoscopy remains essential for comprehensive lesion detection.

  • Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction

    Fukasawa N., Kiyohara H., Adachi T., Sugimoto S., Yoshimatsu Y., Murakami S., Mizushima I., Kaieda Y., Takabayashi K., Tsunoda J., Nakamoto N., Fukunaga K., Taguri M., Mikami Y., Kanai T.

    Journal of Allergy and Clinical Immunology Global 5 ( 2 ) 100625 2026.03

    　View Summary

    Background: 5-Aminosalicylic acid (5-ASA) is a fundamental drug for UC management; however, adverse reactions can lead to poor clinical outcomes and increased health care costs. No objective tests currently exist to predict adverse reactions. This study thus investigated 5-ASA across 4 formulations and addressed a key issue in the treatment of mild to moderate ulcerative colitis (UC). Objective: We aimed to examine the utility of the drug-induced lymphocyte stimulation test (DLST) in predicting successful rotation from mesalazine to sulfasalazine (SASP) in patients with UC. Methods: We retrospectively analyzed the largest cohort to date of patients with UC who were suspected of 5-ASA–associated adverse reactions and underwent DLST. We evaluated the DLST positivity rate for the suspected formulation, cross-reactivity to nonsuspected formulations, and clinical outcomes after rotation from mesalazine to SASP. Results: Mesalazine formulations exhibited a DLST positivity rate of 22.0% (18/82), with 45.1% (37/82) of patients testing positive for at least one 5-ASA formulation. Cross-reactivity between mesalazine and SASP was lower at 12.2% (10/82), likely because of structural differences. Adverse reactions typically developed within 2 weeks of initiating 5-ASA and commonly included fever, diarrhea, and bloody stool. Among patients with mesalazine-associated adverse reactions with DLST-negative test result for SASP, 8 of 12 tolerated the rotation. Rotation failure was mainly associated with a positive or borderline DLST result for mesalazine. Conclusions: DLST serves as a useful diagnostic tool for guiding treatment in patients with UC and suspected 5-ASA–associated hypersensitivity reactions. Prospective multicenter studies are needed to validate its clinical utility.

  • Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan

    Mizushima, I; Yoshimatsu, Y; Kiyohara, H; Sugimoto, S; Sujino, T; Takabayashi, K; Mikami, Y; Kanai, T

    INTESTINAL RESEARCH  2026.02

    ISSN  1598-9100

  • Underestimation of the horizontal extent of ulcerative colitis-associated neoplasia may lead to incomplete endoscopic resection and subsequent recurrence

    Murakami S., Sugimoto S., Iwao Y., Takabayashi K., Kiyohara H., Yoshimatsu Y., Sakakibara R., Kaieda Y., Shigehara A., Hosoe N., Kato M., Mikami Y., Kanai T.

    Therapeutic Advances in Gastroenterology 19   17562848261416193 2026.01

    ISSN  1756283X

    　View Summary

    Background: Endoscopic resection (ER) is increasingly utilized for ulcerative colitis-associated neoplasias (UCANs); however, these lesions demonstrate higher rates of local residuals and recurrences compared with sporadic neoplasias. This may be partly explained by challenges in accurately delineating lesion borders preoperatively, though their clinicopathologic features remain incompletely understood. Objectives: This study aimed to characterize the endoscopic and histologic features associated with local residuals and recurrences following ER for UCAN. Design: A retrospective observational study. Methods: Patients diagnosed with UCAN exhibiting a p53 mutation pattern between 2005 and 2024 and suspected of having local residual or recurrent lesions after ER were included. Endoscopic and histologic features were evaluated. Results: Of 122 UCAN patients, 13 (6 underwent initial ER at our institution before 2018, and 7 underwent initial ER elsewhere) were identified with suspected local residuals or recurrences. Prior to initial ER, p53 immunostaining was not performed in eight cases (five without biopsy and three with biopsy specimens not stained), and only two patients underwent biopsy of the surrounding tissue. Ten tumors had positive or potentially positive horizontal margins (HMs) that were not identified endoscopically at the time of ER. All local recurrences were associated with suspected positive HMs, with a median time to recurrence of 16.5 (8.5–23.8) months. At recurrence, 50% of the lesions appeared flat, while the remaining 50% were superficial elevated lesions with adjacent flat dysplasia. Conclusion: Inadequate preoperative assessment of the horizontal extent of UCANs may contribute to residual or recurrent disease after ER. Comprehensive evaluation—including p53 immunostaining and careful inspection for surrounding flat dysplasia—may improve curative outcomes in UCAN management.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study(Journal of Gastroenterology, (2023), 58, (751–765), 10.1007/s00535-023-02005-7)

    Matsuoka K., Yamazaki H., Nagahori M., Kobayashi T., Omori T., Mikami Y., Fujii T., Shinzaki S., Saruta M., Matsuura M., Yamamoto T., Motoya S., Hibi T., Watanabe M., Fernandez J., Fukuhara S., Hisamatsu T.

    Journal of Gastroenterology (Journal of Gastroenterology)  59 ( 7 ) 644 - 646 2024

    ISSN  09441174

    　View Summary

    Fig. 2h of the original article contained extraneous yellow data bars; Fig. 2h should appear as shown in this correction. (Figure presented.) Proportion of patients reporting a QOL as low, normal or high on SIBDQ; b severe fatigue on FACIT-F; c depression or d anxiety on the HADS scale; e absenteeism, f presenteeism, g work productivity, and h activity impairment on WPAI; and i poor sleep quality on PSQI. FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue, HADS Hospital Anxiety and Depression Scale, PSQI Pittsburgh Sleep Quality Index, QOL quality of life, SIBDQ Short Inflammatory Bowel Disease Questionnaire, WPAI Work Productivity and Activity Impairment In Fig. 3 of the original article, the labelling of ‘y’ axis was reversed (i.e., better/worse outcome); Fig. 3 should appear as shown in this correction. (Figure presented.) Associations of symptom severity and proctocolectomy with patient-reported outcomes. Data indicate SMD and their 95% confidence intervals. The fraction of variance of symptom severity explained by each outcome is shown in parentheses. The magnitude of the effect size was interpreted as: small, SMD = 0.2; medium, SMD = 0.5; and large, SMD = 0.8 [39]. Total number of patients included in the analysis were: SIBDQ (N = 1956), FACIT-F (N = 1935), HADS-D (N = 1958), HADS-A (N = 1958), WPAI-A (N = 1346), WPAI-P (N = 1346), WPAI-L (N = 1346), WPAI-I (N = 1909), and PSQI (N = 1917) (see Table 3 footnotes for breakdown by patient group). FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue, HADS Hospital Anxiety and Depression Scale (A, anxiety; D, depression), PSQI Pittsburgh Sleep Quality Index, SIBDQ Short Inflammatory Bowel Disease Questionnaire, SMD standardized mean difference, WPAI Work Productivity and Activity Impairment (A, absenteeism; I, impairment of activity; L, loss of productivity; P, presenteeism)

  • A second update on mapping the human genetic architecture of COVID-19

    Kanai M., Andrews S.J., Cordioli M., Stevens C., Neale B.M., Daly M., Ganna A., Pathak G.A., Iwasaki A., Karjalainen J., Mehtonen J., Pirinen M., Chwialkowska K., Trankiem A., Balaconis M.K., Veerapen K., Wolford B.N., Ahmad H.F., von Hohenstaufen Puoti K.A., Boer C., Boua P.R., Butler-Laporte G., Cadilla C.L., Colombo F., Douillard V., Dueker N., Dutta A.K., El-Sherbiny Y.M., Eltoukhy M.M., Esmaeeli S., Faucon A., Fave M.J., Cadenas I.F., Francescatto M., Francioli L., Franke L., Fuentes M., Durán R.G., Cabrero D.G., Harry E.N., Jansen P., Szentpéteri J.L., Kaja E., Kirk C., Kousathanas A., Krieger J.E., Patel S.K., Lemaçon A., Limou S., Lió P., Marouli E., Marttila M.M., Medina-Gómez C., Michaeli Y., Migeotte I., Mondal S., Moreno-Estrada A., Moya L., Nakanishi T., Nasir J., Pasko D., Pearson N.M., Pereira A.C., Priest J., Prijatelj V., Prokic I., Teumer A., Várnai R., Romero-Gómez M., Roos C., Rosenfeld J., Ruolin L., Schulte E.C., Schurmann C., Sedaghati-khayat B., Shaheen D., Shivanathan I., Sipeky C., Sirui Z., Striano P., Tanigawa Y., Remesal A.U., Vadgama N., Vallerga C.L., van der Laan S., Verdugo R.A., Wang Q.S., Wei Z., Zainulabid U.A., Zárate R.N., Auton A., Shelton J.F., Shastri A.J., Weldon C.H., Filshtein-Sonmez T., Coker D., Symons A.

    Nature (Nature)  621 ( 7977 ) E7 - E26 2023.09

    ISSN  00280836

  • Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Niemi M.E.K., Karjalainen J., Liao R.G., Neale B.M., Daly M., Ganna A., Pathak G.A., Andrews S.J., Kanai M., Veerapen K., Fernandez-Cadenas I., Schulte E.C., Striano P., Marttila M., Minica C., Marouli E., Karim M.A., Wendt F.R., Savage J., Sloofman L., Butler-Laporte G., Kim H.N., Kanoni S., Okada Y., Byun J., Han Y., Uddin M.J., Smith G.D., Willer C.J., Buxbaum J.D., Mehtonen J., Finucane H., Cordioli M., Martin A.R., Zhou W., Pasaniuc B., Julienne H., Aschard H., Shi H., Yengo L., Polimanti R., Ghoussaini M., Schwartzentruber J., Dunham I., Chwialkowska K., Francescatto M., Trankiem A., Balaconis M.K., Davis L., Lee S., Priest J., Renieri A., Sankaran V.G., Van Heel D., Deelen P., Richards J.B., Nakanishi T., Biesecker L., Kerchberger V.E., Baillie J.K., Mari F., Bernasconi A., Ceri S., Canakoglu A., Wolford B., Faucon A., Dutta A.K., Schurmann C., Harry E., Birney E., Nguyen H., Nasir J., Kaunisto M., Solomonson M., Dueker N., Vadgama N., Limou S., Rahmouni S., Mbarek H., Darwish D., Uddin M.M., Albertos R., Pérez-Tur J., Li R., Folkersen L., Moltke I., Koelling N., Teumer A., Kousathanas A., Utrilla A., Verdugo R.A., Zárate R., Medina-Gómez C., Gómez-Cabrero D., Carnero-Montoro E., Cadilla C.L., Moreno-Estrada A., Garmendia A., Moya L., Sedaghati-Khayat B.

    Nature 621 ( 7977 ) E7 - E26 2023.09

    ISSN  00280836

  • Correction: Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD) (Journal of Gastroenterology, (2022), 57, 11, (867-878), 10.1007/s00535-022-01907-2)

    Matsuoka K., Fujii T., Okamoto R., Yamada A., Kunisaki R., Matsuura M., Watanabe K., Shiga H., Takatsu N., Bamba S., Mikami Y., Yamamoto T., Shimoyama T., Motoya S., Torisu T., Kobayashi T., Ohmiya N., Saruta M., Matsuda K., Matsumoto T., Nakase H., Maemoto A., Shinzaki S., Murata Y., Yoshigoe S., Sasaki A., Yajima T., Hisamatsu T., Nagahori M., Yukawa T., Saito D., Kawai M., Masamune A., Nagasaka M., Kazama T.

    Journal of Gastroenterology (Journal of Gastroenterology)  58 ( 6 ) 602 - 603 2023.06

    ISSN  09441174

    　View Summary

    In the original publication, ‘‘iCREST-CD Study Group’’ was not included in the author list. The correct author list is included in this Correction. Also, an Appendix listing iCREST-CD Study Group collaborators is included in this correction.

  • Correction to: Expert consensus on vaccination in patients with inflammatory bowel disease in Japan (Journal of Gastroenterology, (2023), 58, 2, (135-157), 10.1007/s00535-022-01953-w)

    Ishige T., Shimizu T., Watanabe K., Arai K., Kamei K., Kudo T., Kunisaki R., Tokuhara D., Naganuma M., Mizuochi T., Murashima A., Inoki Y., Iwata N., Iwama I., Koinuma S., Shimizu H., Jimbo K., Takaki Y., Takahashi S., Cho Y., Nambu R., Nishida D., Hagiwara S.i., Hikita N., Fujikawa H., Hosoi K., Hosomi S., Mikami Y., Miyoshi J., Yagi R., Yokoyama Y., Hisamatsu T.

    Journal of Gastroenterology (Journal of Gastroenterology)  58 ( 4 ) 431 - 432 2023.04

    ISSN  09441174

    　View Summary

    The article ‘‘Expert consensus on vaccination in patients with inflammatory bowel disease in Japan’’, written by Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Keisuke Jimbo, Yugo Takaki, Shohei Takahashi, Yuki Cho, Ryusuke Nambu, Daisuke Nishida, Shin-ichiro Hagiwara, Norikatsu Hikita, Hiroki Fujikawa, Kenji Hosoi, Shuhei Hosomi, Yohei Mikami, Jun Miyoshi, Ryusuke Yagi, Yoko Yokoyama, Tadakazu Hisamatsu, was originally published electronically on the publisher’s internet portal on 11 January 2023 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 17 January 2023 to © The Author(s) 2023 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • RESIDENT NON-CLASSICAL MONOCYTES ARE CRITICALLY IMPORTANT FOR TISSUE DESTRUCTION IN ARTHRITIS

    Puchner, Antonia, Saferding, Victoria, Bonelli, Michael, Mikami, Yohei, Goncalves-Alves, Eliana, Binder, Nikolaus B., Steiner, Carl-Walter, Hayer, Silvia, Niederreiter, Birgit, Koenders, Marije M., Smolen, Josef S., Redlich, Kurt, Bluml, Stephan

    ANNALS OF THE RHEUMATIC DISEASES, 

    2017.03

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Elucidation of Neuro-Immune Interactions in Inflammatory Bowel Disease and Development of Novel Treatments Using New Neural Tracing Methods

    2024.06
    -
    2027.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), Principal investigator

    　View Summary

    潰瘍性大腸炎やクローン病に代表される炎症性腸疾患の発症メカニズムは不明ですが、何らかの宿主の遺伝子変異と腸内細菌などの環境因子により免疫が過剰に活性化した結果、慢性的な腸炎が発症すると考えられております。近年、迷走神経をはじめとした自律神経を介した腸と脳の相互連間が、中枢神経の疾患であるうつ病や認知機能障害に加えて腸の疾患である炎症性腸疾患の病態形成に寄与している可能性が示唆されています。本研究では、申請者らのこれまでの報告に基づき、自律神経の機能を解析する新たな研究手法を開発し、自律神経による新たな免疫制御機構を明らかにし、腸炎に関与する新しい治療標的分子の同定を目指します。

  • Comprehensive Understanding of Host Immune-Gut Microbiota Interactions underlying Autoimmune Diseases

    2024.04
    -
    2027.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), No Setting

    　View Summary

    炎症性腸疾患やリウマチ膠原病疾患をはじめとした免疫難病において、腸内細菌等の環境因子による免疫の過剰な活性化は、病態の中核をなすメカニズムと考えられているが、これまで免疫難病病態発症・進展を誘発する病原菌は同定されておらず、免疫難病の発症メカニズムの全貌は未だ解明されていない。本研究課題では、クローン病などの炎症性腸疾患およびリウマチ膠原病疾患を含む免疫難病を自己免疫疾患スペクトラムとして捉えることで、消化管内外における慢性炎症病態の全貌を微生物と宿主免疫間の相互作用の観点から免疫学的、分子生物学的、微生物学的に解明することを目的とする。

  • Elucidation of the gut-liver-brain axis in response to host-invading bacteria and the development of treatments for gastrointestinal immune diseases

    2023.04
    -
    2026.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), No Setting

    　View Summary

    腸内細菌は、腸管疾患だけでなく中枢神経系疾患・肝疾患・皮膚疾患など腸管外病変形成においても重要な役割を担う。申請者は独自解析により腸内細菌の「体内への侵入」と「神経回路の変調」が腸内細菌による病態制御の本質であることを世界に向けて発信した。そこで、本研究提案では、消化器免疫疾患特有の腸内細菌叢が宿主免疫と神経系を介して腸管および腸管外疾患形成に及ぼす影響を分子レベルで解析し、新たな「細菌-腸-脳相関」概念を免疫難病や悪性腫瘍の新規治療法開発に繋げる。

  • Elucidation of the entropy of tissue damage in digestive organs and development of new therapeutic approaches

    2021.08
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, MIKAMI YOHEI, Grant-in-Aid for Transformative Research Areas (B), Principal investigator

    　View Summary

    In this study, we successfully established an intestinal fibrosis model induced by intestinal epithelial detachment to address the lack of model animals in the research of intestinal tissue remodeling or increase in entropy. Using the newly established intestinal fibrosis model animals and human samples, we conducted unbiased analyses of bulk RNA-seq and scRNA-seq data of stromal cells in the intestine, revealing the functional diversity of intestinal resident stromal cells. Furthermore, through integrative multi-omics analysis incorporating transcriptomic and epigenomic analyses such as ATAC-seq, we identified a novel fibroblast population that specifically arises during intestinal fibrosis.

  • Integrated elucidation of inflammatory tissue-resilience and tissue damage-entropy;Creation of innovative science for resolution of inflammation

    2021.08
    -
    2024.03

    Grants-in-Aid for Scientific Research, Hirahara Kiyoshi, Grant-in-Aid for Transformative Research Areas (B), No Setting

    　View Summary

    Aiming to understand "Inflammation Resolution”, this area has developed a research support system (Dr. Hirahara, in charge of research support), enhanced its website (Dr. Mikami, in charge of public relations), and held regular area meetings and symposia (Dr. Arai, in charge of meetings; 4 international symposia, 3 research meetings, monthly online meetings). Professor Yoichi Nabeshima (Kyoto University), Professor Yutaka Kawakami (International University of Health and Welfare, School of Medicine), and Professor Atsushi Iwama (Institute of Medical Science, University of Tokyo), who are conducting advanced research in the field of inflammation, evaluated and provided advice on the entire field.

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • Kitasato Award

    2025.06

    Type of Award： Keio commendation etc.

  • 日本免疫学会研究奨励賞

    2021.12

  • 慶應医学賞 ライジング・スター賞

    2021.01

    Type of Award： Keio commendation etc.

  • 第55回日本消化器免疫学会総会　奨励賞

    2018.12

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • NIH Group Merit Award

    2016.10

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, SURGERY

    2026

  • CLINICAL IMMUNOLOGY

    2026

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2026

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2025

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2025

display all >>

Page Top ▲